AbCellera Biologics (ABCL) EBT (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly EBT came in at -$49.5 million in Q1 2026, up 6.51% YoY from -$46.5 million in Q1 2025, and down 154.05% on a QoQ basis from -$19.5 million in Q4 2025.
AbCellera Biologics (ABCL) EBT (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of EBT data on file, last reported at -$49.5 million in Q1 2026.
- Quarterly EBT rose 6.51% year-over-year to -$49.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.1 million (up 17.32% YoY) and the FY2025 annual result came in at -$177.6 million, up 11.38% from the prior year.
- EBT eased to -$49.5 million in Q1 2026, from -$19.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of $230.8 million in Q1 2022 to a low of -$68.8 million in Q3 2025.
- A 5-year average of -$21.3 million and a median of -$42.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT jumped 286.56% — and 2023, when it plunged 451.9%.
- Tracing ABCL's EBT over 5 years: stood at -$31.4 million in 2022, then slumped by 54.72% to -$48.6 million in 2023, then rose by 3.65% to -$46.8 million in 2024, then soared by 58.36% to -$19.5 million in 2025, then slumped by 154.05% to -$49.5 million in 2026.
- The last three EBT figures came in at -$49.5 million (Q1 2026), -$19.5 million (Q4 2025), and -$68.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -58.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.97 Mn |
| Mar 31, 2026 | -49.54 Mn |
| Dec 31, 2025 | -19.50 Mn |
| Sep 30, 2025 | -68.77 Mn |
| Jun 30, 2025 | -36.34 Mn |
| Mar 31, 2025 | -52.98 Mn |
| Dec 31, 2024 | -46.83 Mn |
| Sep 30, 2024 | -62.63 Mn |
| Jun 30, 2024 | -48.19 Mn |
| Mar 31, 2024 | -42.75 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -39.28 Mn |
| Jun 30, 2023 | -38.00 Mn |
| Mar 31, 2023 | -48.15 Mn |
| Dec 31, 2022 | -31.41 Mn |
| Sep 30, 2022 | 46.59 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | 230.81 Mn |
| Dec 31, 2021 | 84.71 Mn |
| Sep 30, 2021 | -24.97 Mn |